This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richards, W. G. Articles by Sugarbaker, D. J. Search for Related Content PubMed PubMed Citation Articles by Richards, W. G. Articles by Sugarbaker, D. J.

Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma

William G. Richards, Lambros Zellos, Raphael Bueno, Michael T. Jaklitsch, Pasi A. Jänne, Lucian R. Chirieac, Beow Y. Yeap, Rene J. Dekkers, Phillip M. Hartigan, Leah Capalbo, David J. Sugarbaker

From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA

Address reprint requests to David J. Sugarbaker, MD, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115; e-mail: dsugarbaker{at}partners.org

PURPOSE: To evaluate morbidity, mortality, maximum-tolerated dose (MTD), and outcome of intraoperative intracavitary hyperthermic cisplatin lavage in patients undergoing pleurectomy for malignant pleural mesothelioma (MPM).

PATIENTS AND METHODS: Sixty-one patients were prospectively registered. Forty-four resectable patients with MPM underwent pleurectomy, followed by a 1-hour lavage of the resection cavity with dose-escalated cisplatin (50, 100, 150, 175, 200, 225, and 250 mg/m²) at 42°C and then intravenous sodium thiosulfate (16 g/m² over 6 hours). Survival estimates were compared using the log-rank test and proportional hazards regression.

RESULTS: Median age was 71 years (range, 50 to 82 years). Twenty-four patients had epithelial tumors, and 20 had sarcomatous or mixed histology. Postoperative mortality was 11% (five of 44 patients). Dose-limiting renal toxicity occurred at 250 mg/m², establishing the MTD at 225 mg/m². Other morbidity included atrial fibrillation (14 of 44 patients, 32%) and deep venous thrombosis (four of 44 patients, 9%). Median survival time of all registered patients was 9 months, and the median survival time of resected patients was 13 months. Survival estimates differed significantly for resectable patients exposed to low doses (50 to 150 mg/m²; n = 9; median, 6 months) versus high doses (175 to 250 mg/m²; n = 35; median, 18 months) of hyperthermic cisplatin (P = .0019); recurrence-free interval also differed significantly (4 v 9 months, respectively; P < .0001). Low dose level (relative risk = 3.418) and nonepithelial histology (relative risk = 2.336) were independent risk factors for poor survival. Twenty patients with epithelial tumors who underwent high-dose cisplatin lavage had a 26-month median survival time.

CONCLUSION: Pleurectomy and high-dose intraoperative intracavitary hyperthermic cisplatin lavage is feasible in this patient population with restricted surgical options. An apparent dose-related survival benefit warrants further study.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. W. van Sandick, I. Kappers, P. Baas, R. L. Haas, and H. M. Klomp Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution's Experience Ann. Surg. Oncol., June 1, 2008; 15(6): 1757 - 1764. [Abstract] [Full Text] [PDF]

				M. Anraku, K. S. Cunningham, Z. Yun, M.-S. Tsao, L. Zhang, S. Keshavjee, M. R. Johnston, and M. de Perrot Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 823 - 829. [Abstract] [Full Text] [PDF]

				R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. S. Bains, and V. W. Rusch Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 620 - 626. [Abstract] [Full Text] [PDF]

				E. de Bree, S. van Ruth, C. E. Schotborgh, P. Baas, and F. A. N. Zoetmulder Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin Ann. Surg. Oncol., October 1, 2007; 14(10): 3019 - 3026. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				A. E. Martin-Ucar, A. Nakas, J. G. Edwards, and D. A. Waller Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 765 - 770. [Abstract] [Full Text] [PDF]

				I. Opitz, D. Lardinois, S. Arni, S. Hillinger, P. Vogt, B. Odermatt, V. Rousson, and W. Weder Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 772 - 778. [Abstract] [Full Text] [PDF]

				M. H. Pespeni, M. Hodnett, K. S. Abayasiriwardana, J. Roux, M. Howard, V. C. Broaddus, and J.-F. Pittet Sensitization of Mesothelioma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Heat Stress via the Inhibition of the 3-Phosphoinositide-Dependent Kinase 1/Akt Pathway Cancer Res., March 15, 2007; 67(6): 2865 - 2871. [Abstract] [Full Text] [PDF]

				M. Lucchi, A. Chella, F. Melfi, P. Dini, M. Ambrogi, L. Fino, G. Fontanini, and A. Mussi A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 529 - 534. [Abstract] [Full Text] [PDF]

				V. W. Rusch Editorial comment: A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 534 - 535. [Full Text] [PDF]